Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05065983 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine
A Phase 2 study, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT05065983 is a Phase 2 study that has completed, run by Bavarian Nordic. The registered enrollment target is 25 participants.
The verdict
NCT05065983, a Phase 2 study, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The objective of this study is to assess the safety and immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine \[CHIKV VLP\], aluminum hydroxide adjuvanted).
Interventions
- BIOLOGICAL CHIKV VLP, adjuvanted
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-10-11 |
| Est. Completion | 2022-05-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05065983
The ClinicalTrials.gov registry entry for NCT05065983 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CHIKV VLP, adjuvanted is the first listed.
NCT05065983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05065983 about?
NCT05065983 is a clinical study titled "A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine". The objective of this study is to assess the safety and immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine \[CHIKV VLP\], aluminum hydroxide adjuvanted).
What is the current status of trial NCT05065983?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2021-10-11. Estimated completion is 2022-05-05.
What interventions are being tested in trial NCT05065983?
The interventions under investigation include: CHIKV VLP, adjuvanted (BIOLOGICAL).
Who is sponsoring clinical trial NCT05065983?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.